Research programme: AAV-mVChR1 gene therapy - Astellas/CLINO

Drug Profile

Research programme: AAV-mVChR1 gene therapy - Astellas/CLINO

Alternative Names: AAV-mVChR1

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tohoku University
  • Developer Astellas Pharma; CLINO Corporation
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Retinitis pigmentosa

Most Recent Events

  • 01 Feb 2016 Astellas and CLINO Corporation sign a license agreement for the worldwide development and commercialisation of AAV-mVChR1 for the treatment of Retinitis pigmentosa
  • 01 Feb 2016 Early research in Retinitis pigmentosa in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top